CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 18 No. 1
FOCUS ON BREAST CANCER 

Breast MRI before radiation zeroes in on multifocal disease

BY REBEKAH MOAN | January 1, 2009
MRI found cancer sites other than the index tumor in 38% of patients, according to study.

Potential candidates for accelerated partial breast irradiation (APBI) may benefit from pretreatment MRI to ensure no cancer is missed, according to a study conducted by a multidisciplinary group of researchers.

ImaegeBreast MRI reveals mammographically occult cancer foci in 38% of cases, stated Juan Godinez, MD, and his colleagues. Dr. Godinez is from the department of radiation oncology at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, both in Boston.

After lumpectomy, doctors are likely to recommend whole-breast radiation to ensure no tumor cells are missed. APBI in selected patients at low risk for local recurrence is “safe and well tolerated, but long-term recurrences and cosmetic results are not yet available,” the group wrote (Am J Roentgen 191:272-277, 2008).

This retrospective study included 79 women, aged 29 to 75, all eligible for breast-conserving surgery and APBI. Of the 79 patients, 80 additional lesions were seen in the ipsilateral breasts. Of the additional lesions, 57% were found in the same quadrant and the remaining 42% in a diff erent quadrant. Twenty-eight lesions were biopsied by core needle biopsy, 32 lesions were surgically excised and 20 were followed up with MRI at 6 months.

From the 28 core biopsies, 17 showed additional malignancy and 11 were benign. Of the 32 surgical excisions, 28 were malignant and four were benign.

Of the 20 lesions followed up by MRI two patients underwent core needle biopsy with benign results. The remaining 18 lesions were deemed stable.

FigureThe surgical plan for 30 of the 60 patients who underwent core needle or surgical biopsy was changed to a wider excision including mastectomy, according to the researchers. For 19 of the 30 patients with a changed treatment plan, pathology of the surgical biopsy detected 28 additional cancer foci. MRI detected 33 additional foci in the patients. Based on clinical, imaging, and pathology results, 62% of the women were considered eligible for APBI with T1-T2, N0, M0 breast cancer. MRI detected 126 abnormalities, including the index tumors.

Additional cancer sites, other than the index tumors, were found in 38% of patients. Of those patients, 10% had additional cancer in a different quadrant from the index tumor.

“Breast MRI may provide benefit by potentially refining criteria for selecting patients for treatment with accelerated irradiation, with its ability to detect multifocality and additional tumor sites away from the lumpectomy bed,” the researchers wrote.

“Left non-irradiated, occult cancer may give rise to a recurrence that manifests years later,” he said. Thus, he added, MRI “should be part of the work-up for those patients who meet eligibility criteria for [A]PBI and are interested in less than whole breast irradiation.”

The researchers said physical examination and conventional imaging with mammography and sonography are insufficient to exclude additional occult lesions, whereas MRI is more revealing.

 Click here and here to read the Vantage Points.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy